Table 3 Subgroup analysis of coronary disease and total mortality of alcohol intake versus the lowest intake for women compared with men
Outcomes | Subgroup | Low alcohol intake | Moderate alcohol intake | Heavy alcohol intake |
|---|---|---|---|---|
Coronary disease | Country | |||
US | 1.24 (0.72–2.13) | 2.17 (1.12–4.21)* | 1.25 (0.52–3.01) | |
Other | 0.98 (0.80–1.20) | 0.89 (0.75–1.23) | 0.87 (0.62–1.22) | |
Sample size | ||||
>10000 | 0.96 (0.80–1.16) | 0.98 (0.73–1.30) | 0.89 (0.63–1.25) | |
<10000 | 1.42 (0.82–2.45) | 0.93 (0.49–1.78) | 1.00 (0.40–2.49) | |
Adjusted physical activity | ||||
Yes | 1.01 (0.80–1.27) | 0.86 (0.66–1.12) | 0.85 (0.65–1.11) | |
No | 0.96 (0.63–1.48) | 1.24 (0.75–2.05) | 0.91 (0.35–2.38) | |
Adjusted serum cholesterol | ||||
Yes | 1.08 (0.84–1.38) | 0.96 (0.72–1.28) | 1.20 (0.80–1.78) | |
No | 0.93 (0.68–1.27) | 1.00 (0.64–1.57) | 0.75 (0.52–1.08) | |
Adjusted hypertension | ||||
Yes | 1.09 (0.85–1.40) | 0.76 (0.49–1.17) | 1.10 (0.68–1.80) | |
No | 0.92 (0.68–1.26) | 1.11 (0.83–1.48) | 0.77 (0.51–1.15) | |
Adjusted diabetes | ||||
Yes | 0.99 (0.78–1.27) | 0.82 (0.61–1.09) | 0.86 (0.66–1.12) | |
No | 1.01 (0.72–1.40) | 1.22 (0.84–1.78) | 0.83 (0.35–1.97) | |
Follow-up duration | ||||
More than 10 years | 1.01 (0.72–1.40) | 1.09 (0.83–1.43) | 0.86 (0.49–1.54) | |
Less than 10 years | 0.99 (0.78–1.27) | 0.75 (0.48–1.17) | 0.87 (0.63–1.21) | |
Study quality (NOS score) | ||||
8 or 9 | 0.76 (0.50–1.16) | 0.93 (0.74–1.17) | 0.70 (0.42–1.17) | |
<8 | 1.12 (0.90–1.39) | 0.98 (0.63–1.54) | 1.09 (0.76–1.55) | |
Total mortality | Country | |||
US | 1.06 (0.94–1.20) | 1.14 (0.97–1.33) | 1.16 (1.02–1.33)* | |
Other | 1.08 (0.94–1.24) | 1.07 (0.96–1.20) | 1.01 (0.87–1.18) | |
Sample size | ||||
>10000 | 1.06 (0.96–1.16) | 1.09 (0.99–1.19) | 1.08 (0.98–1.20) | |
<10000 | 1.36 (0.91–2.01) | 1.25 (0.77–2.03) | 1.63 (0.87–3.06) | |
Adjusted physical activity | ||||
Yes | 1.10 (0.96–1.26) | 1.08 (0.96–1.20) | 1.02 (0.87–1.18) | |
No | 1.05 (0.93–1.18) | 1.13 (0.97–1.32) | 1.16 (1.01–1.33)* | |
Adjusted serum cholesterol | ||||
Yes | 1.15 (0.73–1.80) | 1.21 (0.79–1.86) | 1.28 (0.61–2.65) | |
No | 1.07 (0.97–1.17) | 1.09 (0.99–1.19) | 1.09 (0.98–1.21) | |
Adjusted hypertension | ||||
Yes | 1.08 (0.94–1.24) | 1.08 (0.87–1.34) | 1.07 (0.83–1.37) | |
No | 1.06 (0.94–1.20) | 1.10 (0.99–1.21) | 1.10 (0.98–1.23) | |
Adjusted diabetes | ||||
Yes | 1.08 (0.93–1.24) | 1.07 (0.96–1.20) | 1.01 (0.87–1.18) | |
No | 1.07 (0.95–1.20) | 1.13 (0.97–1.31) | 1.16 (1.02–1.33)* | |
Follow-up duration | ||||
More than 10 years | 1.08 (0.98–1.19) | 1.09 (0.99–1.20) | 1.10 (0.99–1.22) | |
Less than 10 years | 0.99 (0.72–1.37) | 1.24 (0.76–2.03) | 1.04 (0.76–1.43) | |
Study quality (NOS score) | ||||
8 or 9 | 1.08 (0.95–1.23) | 1.08 (0.97–1.21) | 1.03 (0.88–1.20) | |
<8 | 1.06 (0.93–1.21) | 1.11 (0.95–1.30) | 1.15 (1.00–1.31)* | |